CVS Health Corp. has reportedly launched a new prescription drug plan that encourages customers to fill prescriptions at stores that do not sell tobacco products, like CVS. But according to some antitrust experts, the new incentives could raise antitrust concerns.
Reports say the plan charges prescription refill copays of up to $15 more when customers fill prescriptions at a store that sells tobacco products. Those stores include CVS rivals Walgreens, Rite-Aid and others.
While CVS says the new plan was the product of calls for a tobacco-free pharmacy network, experts say there could be legal trouble ahead as the program could unfairly steer customers towards CVS stores.
Former Federal Trade Commission executive David Balto, who is currently an antitrust attorney, says the pharmacy plan is concerning. “There’s no cost savings that comes about from limiting the network,” he said. “it’s really another effort to limit the ability of their rivals to effectively compete.”
The head of the Independent Pharmacy Alliance, John Giampolo, agrees. “It’s an unfair competitive practice,” he said.
Full content: Yahoo Finance
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
CVS Health Explores Potential Breakup Amid Investor Pressure: Report
Oct 3, 2024 by
CPI
DirecTV Acquires Dish TV, Creating 20 Million-Subscriber Powerhouse
Oct 3, 2024 by
CPI
South Korea Fines Kakao Mobility $54.8 Million for Anti-Competitive Practices
Oct 3, 2024 by
CPI
Google Offers Settlement in India’s Antitrust Case Regarding Smart TVs
Oct 3, 2024 by
CPI
Attorney Challenges NCAA’s $2.78 Billion Settlement in Landmark Antitrust Cases
Oct 3, 2024 by
nhoch@pymnts.com
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh